We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $11.5B
1-Year Est. Return 168.77%
This Fund
S&P 500
This Quarter Est. Return
+139.21%
1 Year Est. Return
+168.77%
3 Year Est. Return
+596.08%
5 Year Est. Return
+846.46%
10 Year Est. Return
+54,223.74%
AUM
$3.3B
AUM Growth
+$1.62B
Cap. Flow
+$431M
Cap. Flow %
13.06%
Top 10 Hldgs %
71.48%
Holding
41
New
9
Increased
7
Reduced
2
Closed
7

Top Buys

Rank Stock Value
1
PHAT icon
Phathom Pharmaceuticals
PHAT
+$91.7M
2
ETNB
89bio
ETNB
+$88M
3
ARVN icon
Arvinas
ARVN
+$58.8M
4
CCXI
ChemoCentryx, Inc.
CCXI
+$56.2M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$44.4M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$35.3M
2
MYOV
Myovant Sciences Ltd.
MYOV
+$32.1M
3
DTIL icon
Precision BioSciences
DTIL
+$15.5M
4
KOD icon
Kodiak Sciences
KOD
+$14.7M
5
AXSM icon
Axsome Therapeutics
AXSM
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THOR
1
DELISTED
Synthorx, Inc. Common Stock
THOR
$680M 20.61%
9,724,598
– –
ASND icon
2
Ascendis Pharma A/S
ASND
$15.8B
$582M 17.66%
4,185,342
+52,900
+1% +$5.88M
RARX
3
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$228M 6.91%
4,858,260
– –
ARVN icon
4
Arvinas
ARVN
$540M
$151M 4.58%
3,672,872
+2,009,360
+121% +$58.8M
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
$127M 3.84%
+3,199,389
New +$56.2M
RYTM icon
6
Rhythm Pharmaceuticals
RYTM
$6.66B
$124M 3.78%
5,422,312
+2,000,000
+58% +$44.4M
EIDX
7
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$124M 3.76%
2,162,671
– –
ZGNX
8
DELISTED
Zogenix, Inc.
ZGNX
$118M 3.57%
2,260,751
– –
PHAT icon
9
Phathom Pharmaceuticals
PHAT
$660M
$114M 3.44%
+3,646,808
New +$91.7M
TGTX icon
10
TG Therapeutics
TGTX
$8.12B
$110M 3.33%
9,880,323
+3,000,000
+44% +$22.8M
STSA
11
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$92.1M 2.79%
4,681,858
– –
ORTX
12
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$87.9M 2.66%
638,990
+116,542
+22% +$14.2M
ETNB
13
DELISTED
89bio
ETNB
$83.1M 2.52%
+3,161,214
New +$88M
FTSV
14
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$76.1M 2.31%
+1,933,250
New +$31.1M
WVE icon
15
Wave Life Sciences
WVE
$879M
$62.3M 1.89%
7,775,207
– –
TVTX icon
16
Travere Therapeutics
TVTX
$5.89B
$60.4M 1.83%
4,252,453
+264,893
+7% +$3.38M
BOLD
17
DELISTED
Audentes Therapeutics, Inc
BOLD
$54M 1.64%
+902,383
New +$33.9M
PRVL
18
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$53.2M 1.61%
3,363,605
– –
CRNX
19
DELISTED
Crinetics Pharmaceuticals
CRNX
$47M 1.43%
1,875,209
– –
ARDX icon
20
Ardelyx
ARDX
$878M
$40.2M 1.22%
+5,358,863
New +$32.6M
AXSM icon
21
Axsome Therapeutics
AXSM
$10.7B
$38M 1.15%
367,816
-296,569
-45% -$12M
IGMS
22
DELISTED
IGM Biosciences
IGMS
$37.5M 1.14%
982,723
+516,355
+111% +$13M
STOK icon
23
Stoke Therapeutics
STOK
$1.82B
$31.7M 0.96%
1,119,963
– –
RLMD icon
24
Relmada Therapeutics
RLMD
$474M
$29.7M 0.9%
+761,666
New +$23.1M
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$28.5M 0.87%
+1,445,801
New +$23.1M
1
2

Similar funds

AAIS
ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $11.5B AUM 18.82% 1-Year Est. Return
CC
Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return
AI
Axiom Investors Greenwich, Connecticut $11.6B AUM 69.67% 1-Year Est. Return
BMSSC
B. Metzler seel. Sohn & Co Frankfurt, Germany $11.6B AUM 34.29% 1-Year Est. Return
HTC
Haverford Trust Company Radnor, Pennsylvania $11.6B AUM 18.97% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

RA Capital Management's Q4 2019 Portfolio in Review

As of Q4 2019, RA Capital Management held 41 positions worth $3.3B, up 96% from $1.68B the previous quarter. Its ten largest holdings account for 71% of the portfolio.

RA Capital Management deployed $431M of net new capital in Q4 2019, opening 9 new positions and adding to 7 existing holdings. Its largest new stake was Phathom Pharmaceuticals: 3,646,808 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Axsome Therapeutics, an estimated $12M trimmed.

  • RA Capital Management's largest Q4 2019 buy was Phathom Pharmaceuticals: 3,646,808 shares worth $114M.
  • RA Capital Management added most to Arvinas in Q4 2019, an estimated $58.8M increase.
  • RA Capital Management's biggest Q4 2019 reduction was Axsome Therapeutics, cutting an estimated $12M.
  • RA Capital Management fully exited Dicerna Pharmaceuticals, Inc. in Q4 2019, selling an estimated $35.3M.
  • RA Capital Management's ten largest holdings make up 71% of its $3.3B portfolio in Q4 2019.
  • RA Capital Management opened 9 new positions and closed 7 in Q4 2019.
  • RA Capital Management's portfolio value rose 96% quarter-over-quarter to $3.3B.

Based on RA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.